Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction

被引:29
|
作者
Sonowal, Himangshu [1 ]
Pal, Pabitra [1 ]
Shukla, Kirtikar [1 ]
Saxena, Ashish [1 ]
Srivastava, Satish K. [1 ]
Ramana, Kota V. [1 ]
机构
[1] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA
关键词
Aldose reductase; Fidarestat; Doxorubicin; Endothelial cells; Cardiotoxicity; BREAST-CANCER PATIENTS; FACTOR-KAPPA-B; NITRIC-OXIDE; INDUCED CARDIOTOXICITY; INDUCED CARDIOMYOPATHY; COLON-CANCER; MOLECULAR-MECHANISMS; UP-REGULATION; IN-VIVO; INFLAMMATION;
D O I
10.1016/j.bcp.2018.02.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite doxorubicin (Dox) being one of the most widely used chemotherapy agents for breast, blood and lung cancers, its use in colon cancer is limited due to increased drug resistance and severe cardiotoxic side effects that increase mortality associated with its use at high doses. Therefore, better adjuvant therapies are warranted to improve the chemotherapeutic efficacy and to decrease cardiotoxicity. We have recently shown that aldose reductase inhibitor, fidarestat, increases the Dox-induced colon cancer cell death and reduces cardiomyopathy. However, the efficacy of fidarestat in the prevention of Dox-induced endothelial dysfunction, a pathological event critical to cardiovascular complications, is not known. Here, we have examined the effect of fidarestat on Dox-induced endothelial cell toxicity and dysfunction in vitro and in vivo. Incubation of human umbilical vein endothelial cells (HUVECs) with Dox significantly increased the endothelial cell death, and pre-treatment of fidarestat prevented it. Further, fidarestat prevented the Dox-induced oxidative stress, formation of reactive oxygen species (ROS) and activation of Caspase-3 in HUVECs. Fidarestat also prevented Dox-induced monocyte adhesion to HUVECs and expression of ICAM-1 and VCAM-1. Fidarestat pre-treatment to HUVECs restored the Dox-induced decrease in the Nitric Oxide (NO)-levels and eNOS expression. Treatment of HUVECs with Dox caused a significant increase in the activation of NF-kappa B and expression of various inflammatory cytokines and chemokines which were prevented by fidarestat pre-treatment. Most importantly, fidarestat prevented the Doxinduced mouse cardiac cell hypertrophy and expression of eNOS, iNOS, and 3-Nitrotyrosine in the aorta tissues. Further, fidarestat blunted the Dox-induced expression of various inflammatory cytokines and chemokines in vivo. Thus, our results suggest that by preventing Dox-induced endothelial cytotoxicity and dysfunction, AR inhibitors could avert cardiotoxicity associated with anthracycline chemotherapy.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 50 条
  • [21] Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity
    El-Kabbani, O
    Carbone, V
    Darmanin, C
    Oka, M
    Mitschler, A
    Podjarny, A
    Schulze-Briese, C
    Chung, RPT
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (17) : 5536 - 5542
  • [22] The Aldose Reductase Inhibitor Fidarestat Suppresses Ischemia-Reperfusion-Induced Inflammatory Response in Rat Retina
    Agardh, Carl-David
    Agardh, Elisabet
    Obrosova, Irina G.
    Smith, Maj-Lis
    PHARMACOLOGY, 2009, 84 (05) : 257 - 263
  • [23] Aldose reductase regulates doxorubicin-induced immune and inflammatory responses by activating mitochondrial biogenesis
    Sonowal, Himangshu
    Saxena, Ashish
    Qiu, Sumin
    Srivastava, Sanjay
    Ramana, Kota V.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 895
  • [24] Therapeutic effect of fidarestat, aldose reductase inhibitor, on an accelerated atherosclerosis with hyperglycemia in mice: Involvement of endothelial nitric oxide production
    Goto, M
    Okuyama, M
    Taniko, K
    Ichikawa, K
    Kato, N
    Nakayama, Y
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 51 - 51
  • [25] APC loss prevents doxorubicin-induced cell death by effluxing drug and increasing a chemoresistant cell population
    Stefanski, Casey D.
    Kotsen, Janna
    Bernard, Amy
    Prosperi, Jenifer
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice
    Takaaki Furihata
    Satoshi Maekawa
    Shingo Takada
    Naoya Kakutani
    Hideo Nambu
    Ryosuke Shirakawa
    Takashi Yokota
    Shintaro Kinugawa
    BMC Pharmacology and Toxicology, 22
  • [27] Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice
    Furihata, Takaaki
    Maekawa, Satoshi
    Takada, Shingo
    Kakutani, Naoya
    Nambu, Hideo
    Shirakawa, Ryosuke
    Yokota, Takashi
    Kinugawa, Shintaro
    BMC PHARMACOLOGY & TOXICOLOGY, 2021, 22 (01):
  • [28] Non-coding RNA Regulation of Doxorubicin-induced Cardiac Cell Death and Dysfunction
    Henderson, John
    Patil, Mallikarjun
    Luong, Hien T.
    Annamalai, Divya
    Phuong Quach
    Namakkal-Soorappan, Rajasekaran
    Krishnamurthy, Prasanna
    CIRCULATION, 2019, 140
  • [29] Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina
    Obrosova, Irina G.
    Maksimchyk, Yury
    Pacher, Pal
    Agardh, Elisabet
    Smith, Maj-Lis
    El-Remessy, Azza B.
    Agardh, Carl-David
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 (01) : 135 - 142
  • [30] Berberine prevents Doxorubicin-induced cardiotoxicity through modulation of cell death and autophagy in rat cardiomyoblasts
    Martins, T. R.
    Deus, C.
    Oliveira, P. J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2015, 45 : 28 - 28